Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).

Plain-language guide to PMID 34802788 (2021): open-label randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 40 patients.

Key Facts

PMID: 34802788
Journal: Vaccine
Year: 2021
Study type: Randomized Controlled Trial
Authors: Hafner-Giessauf H et al. (7 authors)
DOI: 10.1016/j.vaccine.2021.11.029

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Patients with advanced chronic kidney disease should be vaccinated against hepatitis B.

The effect of cholecalciferol supplementation on hepatitis B vaccination response in haemodialysis patients with vitamin D insufficiency is unknown.

Who Took Part

The abstract describes 40 patients taking part.

PubMed tags the participants as both men and women.

In this randomized open label pilot study 40 unvaccinated haemodialysis patients with 25(OH)D insufficiency (<30 ng/mL) were enrolled.

In the control group, patients were vaccinated immediately after randomization.

How the Study Was Run

The researchers set it up as a randomized, open-label and pilot study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the patients and staff both knew the treatment.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Anti-hepatitis B-antibody titer (anti-HBs) was measured eight weeks after completing the vaccination course.

What Was Measured

Topics PubMed links to this paper include Cholecalciferol, Dietary Supplements, Hepatitis B, Pilot Projects, Renal Dialysis, Vaccination and Vitamin D.

Author keywords: Haemodialysis, Hepatitis B vaccination, Vitamin D insufficiency and Vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Vitamin D, K2, Magnesium and Zinc in 40 patients.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Vaccine), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.